In 2018, Bayer took over Monsanto for a purchase price of $66 billion. Monsanto sold a genetically modified herbicide product, Roundup, which utilized glyphosate, a highly toxic chemical suspected of causing cancer and harming human health. Various verdicts in the United States have classified glyphosate as a known carcinogen resulting in substantial damages being payable by Monsanto.
The case is brought on behalf of investors in Bayer who allege that Bayer did not disclose the legal and commercial risks associated with the use of glyphosate and the corresponding risks to Monsanto and therefore to Bayer and its shareholders post-acquisition.
The case is an example of utilisation of German capital markets disclosure rules as a means of securing redress for investors’ losses.
Therium is co-funding the claims with law firm DRRT on behalf of the institutional investors.
Securities Claim / Shareholder Dispute / Group Litigation / Collective Redress / Investor Loss
Pharmaceutical
You may unsubscribe at any time. View our privacy policy
